(0.60%) 5 158.55 points
(0.36%) 38 815 points
(0.61%) 16 255 points
(0.70%) $78.66
(3.17%) $2.21
(1.20%) $2 336.30
(3.15%) $27.53
(0.78%) $972.85
(-0.19%) $0.927
(-0.55%) $10.81
(-0.30%) $0.795
(-0.06%) $91.39
0.45% $ 5.96
Live Chart Being Loaded With Signals
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands...
Stats | |
---|---|
Tagesvolumen | 1 081.00 |
Durchschnittsvolumen | 10 468.00 |
Marktkapitalisierung | 3.77B |
EPS | $0.782 ( 2023-09-30 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-07-25 |
Last Dividend | $0.0640 ( 2023-07-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.69 |
ATR14 | $0 (0.00%) |
Hypera S.A. Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Hypera S.A. Finanzdaten
Annual | 2023 |
Umsatz: | $7.91B |
Bruttogewinn: | $4.85B (61.30 %) |
EPS: | $2.61 |
FY | 2023 |
Umsatz: | $7.91B |
Bruttogewinn: | $4.85B (61.30 %) |
EPS: | $2.61 |
FY | 2022 |
Umsatz: | $7.55B |
Bruttogewinn: | $4.76B (63.10 %) |
EPS: | $2.68 |
FY | 2021 |
Umsatz: | $5.94B |
Bruttogewinn: | $3.80B (64.05 %) |
EPS: | $2.11 |
Financial Reports:
No articles found.
Hypera S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0590 (N/A) |
$0.117 (N/A) |
$0 (N/A) |
$0.0590 (N/A) |
$0.0640 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0770 | 2011-05-10 |
Last Dividend | $0.0640 | 2023-07-06 |
Next Dividend | $0 | N/A |
Payout Date | 2023-09-09 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | $2.45 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.13 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.91 | |
Div. Directional Score | 7.75 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SPKKY | Ex Dividend Knight | 2023-09-14 | Annually | 0 | 0.00% | |
GTPS | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
AGESY | Ex Dividend Junior | 2023-10-25 | Annually | 0 | 0.00% | |
NIDB | Ex Dividend Knight | 2023-08-10 | Bi-Monthly | 0 | 0.00% | |
CNTHO | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
TKAGY | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
HWDJY | Ex Dividend Knight | 2023-10-12 | Annually | 0 | 0.00% | |
ASCCY | Ex Dividend Junior | 2023-06-28 | Annually | 0 | 0.00% | |
PNBI | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
DTCWY | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.212 | 1.500 | 5.77 | 8.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0604 | 1.200 | 7.99 | 9.58 | [0 - 0.3] |
returnOnEquityTTM | 0.149 | 1.500 | 9.45 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0801 | -1.000 | 9.20 | -9.20 | [0 - 1] |
currentRatioTTM | 1.807 | 0.800 | 5.97 | 4.77 | [1 - 3] |
quickRatioTTM | 1.314 | 0.800 | 6.98 | 5.58 | [0.8 - 2.5] |
cashRatioTTM | 0.662 | 1.500 | 7.43 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.378 | -1.500 | 3.69 | -5.54 | [0 - 0.6] |
interestCoverageTTM | 2.28 | 1.000 | -0.266 | -0.266 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.866 | 2.00 | 9.07 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.910 | -1.500 | 6.36 | -9.54 | [0 - 2.5] |
grossProfitMarginTTM | 0.615 | 1.000 | 3.09 | 3.09 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.327 | 1.000 | 5.45 | 5.45 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.183 | 1.000 | -0.0935 | -0.0935 | [0.2 - 2] |
assetTurnoverTTM | 0.286 | 0.800 | -1.429 | -1.143 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.20 | 1.000 | 8.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.149 | 2.50 | 9.65 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.866 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.178 | 1.500 | 5.56 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0801 | 1.500 | 9.20 | -9.20 | [0 - 1] |
pegRatioTTM | 0.0394 | 1.500 | -3.07 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.243 | 1.000 | 6.43 | 0 | [0.1 - 0.5] |
Total Score | 5.91 |
Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.